Medication topics
Natalizumab articles covering Tysabri, anti-integrin therapy, safety considerations, access, and IBD treatment decisions. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
7 articles
Market and late-stage trial updates can indicate which new therapies may become available and influence treatment options, access, and research priorities for Crohn's disease over the coming years.
Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Natalizumab, and Biosimilars.
If approved, a vedolizumab biosimilar could increase treatment options and competitive pricing for adults with moderate-to-severe ulcerative colitis or Crohn's disease. The company already markets a natalizumab...
A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...
